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POTENTIAL IMPACT OF HEALTH STATUS ON LIFE
SATISFACTION AND QUALITY OF LIFE:A PILOT STUDY
Chongpison Y, Ramachandran S, Craig BM, Coons SJ
University of Arizona, College of Pharmacy,Tucson, AZ, USA
OBJECTIVES: To better understand the human beneﬁts of main-
taining or enhancing health, more research is needed to assess
the impact of health status on individuals’ perceptions of their
life satisfaction and quality of life. The purpose of this pilot 
study was to explore the relationship between health status 
and 1) satisfaction with life as a whole, and 2) overall quality of
life. METHODS: A total of 314 participants were recruited 
from the general population of the Tucson Metropolitan Area to
complete a touch screen computer-based questionnaire. The
questionnaire included, among other items and scales, the EQ-
5D and items assessing satisfaction with life in general (ﬁve-
point scale from very dissatisﬁed to very satisﬁed) and overall
quality of life (ﬁve-point scale from poor to excellent). Quadratic
regression and ordered logit models were estimated to assess the
potential impact of health status. RESULTS: The quadratic
regression results suggest a curvilinear relationship between
health status (EQ-VAS) and overall quality of life (b-coefﬁcients:
b1 = -0.022 and b2 = 0.004). Self-reported health status is 
positively related to quality of life, and health status is more
inﬂuential when a person has better health. However, our 
estimates reject the quadratic relationship in favor of a linear
relationship between health status and life satisfaction. CON-
CLUSIONS: Our results suggest that the contribution of health
status to quality of life is not constant across health. Health
status may be a more important factor when person is healthy.
However, the impact of health status on life satisfaction appears
constant across levels of health. These ﬁndings conﬁrm that 
satisfaction with life as a whole and overall quality of life are
related but are measuring different constructs. This suggests 
that the perceived value of outcomes, as opposed to satisfaction
with the outcomes, may depend on the health of the person
affected.
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SELF-ASSESSED HEALTH STATUS IN THE UNITED STATES:
EQ-5D FINDINGS FROM THE MEDICAL EXPENDITURE 
PANEL SURVEY
Craig BM1, Ramachandran S2, Coons SJ3
1University of Arizona,Tucson, AZ, USA; 2University of Arizona
College of Pharmacy,Tucson, AZ, USA; 3College of Pharmacy,Tucson,
AZ, USA
OBJECTIVES: To measure population health in the United
States. METHODS: We examine the EQ-5D responses from the
2000 and 2001 Medical Expenditure Panel Survey data. Under
the EuroQol descriptive system, respondents assess their health
on ﬁve dimensions (mobility, self-care, usual activity, pain/
discomfort, and anxiety/depression), each of which has three
levels. We further supplement the descriptive system by arrang-
ing the EQ-5D states into four categories (“Very Good”,
“Good”, “Fair” and “Poor”) according to average self-assessed
health status on 5-point and 101-point scales. RESULTS: In
2000, 45% of non-institutionalized adults in the United States
had no problems on all 5 dimensions; 30% had no problems
other than moderate pain or discomfort or being moderately
anxious or depressed; and 6% of adults were in “Fair” or “Poor”
EQ-5D states. Between 2000 and 2001, the prevalence of “Very
Good” and “Poor” EQ-5D States increased which suggests that
health inequality among the US adult population may have
increased over this period. CONCLUSION: Using the EuroQol
descriptive system, shifts and inequity in population health can
be montiored for policy purposes, similar to a health gross
domestic product.
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INTERPRETING THE MAGNITUDE OF SCORE DIFFERENCES
IN THE SF-36 VITALITY SCALE:ASSOCIATION WITH CLINICAL
CONDITIONS AND OUTCOMES
Wallenstein GV1, Bjorner JB1, Martin MC1, Mody SH2, Piech CT2
1QualityMetric Incorporated, Lincoln, RI, USA; 2Ortho Biotech Clinical
Affairs LLC, Bridgewater, NJ, USA
OBJECTIVE: To evaluate the association between differences in
scores of the SF-36 Vitality (VT) scale with clinical conditions
and outcomes. METHODS: Analyses were performed on data
from the Medical Outcomes Study (n = 3445) and the National
Survey of Functional Health Status (n = 2909). The strategy for
establishing the clinical and outcomes signiﬁcance for the VT
scale (0–100 scale) consisted of two components: 1) comparing
VT scores in patients with and without clinical conditions with
well-understood effects on VT/fatigue; and 2) investigating
whether VT score differences of ﬁve-and ten-points predict out-
comes. The ﬁrst analysis used multivariate regression to evalu-
ate the association between chronic disease conditions and VT.
To approximate the impact of within patient VT differences, the
second set of analyses used logistic regression models to examine
the relationship between baseline VT scores and four outcomes:
1) inability to work due to health; 2) subsequent job loss; 3) sub-
sequent hospitalization, all at one year; and 4) mortality at seven
years. RESULTS: VT scores were signiﬁcantly reduced in patients
with anemia (ﬁve-six points), CHF (six points), and COPD
(seven-ten points). Both ﬁve-and ten-point decreases in VT score
were signiﬁcantly associated with increased odds of negative 
outcomes, including inability to work due to health (OR(5) =
1.28, OR(10) = 1.62), job loss (OR(5) = 1.13, OR(10) = 1.28),
hospitalization (OR(5) = 1.08, OR(10) = 1.17), and mortality
(OR(5) = 1.08–1.28, OR(10) = 1.14–1.54, depending on VT
level). Absolute risk for these negative outcomes increased non-
linearly with decreasing VT. CONCLUSIONS: VT scores are
reduced in patients with serious medical diseases. Differences of
ﬁve-ten points in the VT score were associated with signiﬁcant
increased risk of negative outcomes. A ten-point lower VT score
was consistent with 62%, 28%, and 17% increased likelihood
of inability to work, job loss, and hospitalization, respectively,
by one year. Similarly, a lower VT score was associated with an
increased risk of death by seven years.
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PATIENTS’ PERSPECTIVES OF TREATMENT SATISFACTION:
A QUALITATIVE RESEARCH EVALUATION
Colman S, Miller T
Quintiles, San Francisco, CA, USA
OBJECTIVES: We collected and analyzed qualitative data in
order to evaluate the domains of a patient reported, treatment
satisfaction measure, the Treatment Satisfaction Questionnaire
for Medication (TSQM©). METHODS: Qualitative data was
obtained through three geographically-distributed patient focus
groups (N = 27), convened in Los Angeles, Chicago, and Boston.
Participants had the following medical conditions: asthma,
arthritis, cancer, cardiovascular disease, depression/anxiety, dia-
betes, infectious disease, migraine, and psoriasis. Content analy-
sis was conducted on qualitative data for a patient perspective
of domains of treatment satisfaction within the TSQM©.
RESULTS: The results contribute to a deeper understanding of
treatment satisfaction. The following domains were supported
through our qualitative analyses: effectiveness, side effects, con-
venience, and impact on daily life/functioning. Patient quotes
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illuminated and provided evidence for each domain discussed.
Effectiveness was identiﬁed by patients as the most important
consideration for satisfaction, irrespective of the patient’s condi-
tion. Effectiveness comprised 1) consistency of effect; 2) time
before onset of effect; 3) degree of symptom relief; and 4) dura-
tion. Side effects were also identiﬁed as among the most impor-
tant considerations for satisfaction, and some patients, such as
those on chemotherapy, identiﬁed it as the most important con-
sideration. If two drugs have the same effectiveness, then side
effects become most important. Convenience was found to be
important because it impacts lifestyle and consists of three com-
ponents: ease-of-use, drug form and/or mode of administration,
and administrative characteristics. Finally, patients were greatly
concerned about the impact their treatment would have on their
ability to function in their daily activities. CONCLUSIONS: This
study contributes to the understanding of medication treatment
satisfaction from the patient’s perspective. Rigorous qualitative
methodology was used to assess the domain structure of a new
instrument developed and validated to measure treatment satis-
faction across therapeutic areas (TSQM©).
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LINGUISTIC VALIDATION OF THE US SPANISH WORK
PRODUCTIVITY AND ACTIVITY IMPAIRMENT
QUESTIONNAIRE, GENERAL HEALTH VERSION (WPAI:GH)
Gawlicki MC1, Reilly MC2, Popielnicki A1, Reilly K2
1Corporate Translations, Inc, Mansﬁeld Center, CT, USA; 2Margaret
Reilly Associates, Inc, New York, NY, USA
OBJECTIVES: There are no measures of health-related absen-
teeism and presenteeism validated for use in the large and
increasing US Spanish-speaking population. The ﬁrst steps in
adapting an English language questionnaire for use in this pop-
ulation involve a reiterative process of creating harmonized
forward and back translations by independent translators and
cognitive debrieﬁng of subjects following questionnaire admin-
istration. This process (linguistic validation) establishes the 
conceptual equivalence of the translation to the original and the
cultural appropriateness of the translation. METHODS: To eval-
uate the linguistic validity of the US Spanish version of the Work
Productivity and Activity Impairment questionnaire, General
Health Version (WPAI:GH), a bilingual (Spanish-English) inter-
viewer debriefed subjects after self-administration of the US
Spanish (N = 31) and English (N = 35) WPAI:GH. Subjects were
stratiﬁed equally by educational level, with and without a high
school degree. RESULTS: The item comprehension rate was
98.6% for Spanish and 99.6% for English. Response revision
rates during debrieﬁng were 1.6% for Spanish and 0.5% for
English. Responses to hypothetical scenarios indicate that both
language versions adequately differentiate sick time taken for
health and non-health reasons and between absenteeism and pre-
senteeism. CONCLUSION: Linguistic validity of the US Spanish
translation of the WPAI:GH was established among a diverse US
Spanish-speaking population, including those with minimal 
education.
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RECONSIDERING THE PERSPECTIVE IN 
ECONOMIC EVALUATION
Seoane-Vazquez EC, Visaria J, Parekh A
Ohio State University, Columbus, OH, USA
OBJECTIVES: Perspective is the point of view from which costs
and outcomes of an economic evaluation are evaluated. The
results and interpretation of the evaluation depend upon the per-
spective used. This study evaluates the use of perspective in eco-
nomic evaluation based on a review of literature, guidelines and
current articles. METHODS: A review of the concept and rec-
ommended use of perspective in theoretical literature and 31 eco-
nomic evaluation guidelines was performed. The practical use of
perspective was assessed in the 30 economic evaluations pub-
lished in the Core25 Journals, Health Economics and Pharma-
coeconomics in 2004. RESULTS: The use of societal perspective,
including all relevant costs and outcomes, was unanimously rec-
ommended by the literature and the majority of the guidelines.
No source mentioned the possibility and implications of using
different perspectives for assessing both costs and outcomes in
the same study. All articles reviewed used a different perspective
for assessing both costs and outcomes. For assessing costs, the
payer perspective was most preferred (22), followed by the soci-
etal perspective (4) and other (4). In the case of the outcomes,
the patient perspective or outcomes for a patient or person at
risk was used a majority of the time (29), followed by family
perspective (1). CONCLUSIONS: The ﬁndings of different per-
spectives for assessing outcomes and cost in the same study con-
tradict the conventional wisdom. This affects the interpretation
of the results and implications of the study. We recommend the
following: 1) explicitly state the perspective used for assessing
both, costs and outcomes; 2) the use of the same perspective for
both, costs and outcomes; and 3) the sum of individual patient
perspectives should not be understood as the societal perspective
because it excludes outcomes such as effects on the mental health
of patients’ families.
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